Virus therapy takes on Hard-to-Treat cancers
NCT ID NCT05427487
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the virus can shrink tumours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IVX037 (a virus that targets and kills cancer cells) and sintilimab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumours that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 70 participants, so safety and dosing are still being figured out. The virus may not shrink tumours or could cause side effects like flu-like symptoms or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melbourne Site
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact
-
South Australia site
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
Sydney site
RECRUITINGSydney, New South Wales, 2000, Australia
Contact